From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on Tcells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces Tcell activation and proliferation .
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on Tcells and induces Tcell-mediated cytotoxicity leading to Tcell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate Tcells. Muromonab blocks the function of Tcell receptors to recognize foreign antigens and inhibits Tcell-mediated immune responses, including cell-mediated lymphocyte lysis and Tcell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic Tcells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces Tcell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on Tcells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates Tcells by simultaneously binding to CD123 in target cells and CD3 in effector Tcells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/Tcell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of Tcells, recruiting Tcells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive Tcells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
Lipid C2 is an ionizable cationic lipid that has been used in the formation of lipid nanoparticles (LNP) for mRNA delivery in vivo. LNPs containing Lipid C2 and encapsulating an mRNA reporter selectively accumulate in the liver and spleen but not the heart, lungs, or kidneys in mice. LNP containing Lipid C2 and encapsulating mRNA encoding the Epstein-Barr virus (EBV) protein latent membrane protein 2 (LMP-2), in combination with an anti-programmed cell death protein 1 (PD-1) antibody, decrease tumor volume and reverse Tcell exhaustion, as well as increase the percentage of CD3+CD8 + central and CD3+CD8 + effector memory Tcells and decrease the percentage of CD3+Tcells expressing Pd-1, in the spleen in a CT26 murine EBV-infected colon cancer model .
Cibisatamab, a Tcell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on Tcells. Cibisatamab triggers Tcell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of Tcells, thereby directing Tcells to multiple myeloma (MM) cells expressing BCMA and activating Tcells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on Tcells .
PD-1/PD-L1-IN 6 (compound A13) is a potent PD-1/PD-L1 interaction inhibitor, with an IC50 of 132.8 nM. PD-1/PD-L1-IN 6 exhibits outstanding immunoregulatory activity. PD-1/PD-L1-IN 6 significantly elevates interferon-γ secretion in a Hep3B/OS-8/hPD-L1 and CD3Tcell co-culture model, without significant toxic effect. PD-1/PD-L1-IN 6 restores the immune response in a Tcell-tumor co-culture model .
PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3Tcells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating Tcells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates Tcell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
ERY-974 is a T-cell-engaging bispecific antibody (TCB) targeting GPC3. ERY-974 binds to both GPC3 and the CD3 receptor on Tcells simultaneously, activating Tcells and prompting them to release perforin and granzyme, triggering apoptosis of tumor cells. ERY-974 is promising for research of solid tumors, such as liver cancer .
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on Tcells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of Tcells against MM tumor cells .
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic Tcells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC50 of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ Tcells, and enhances Tcell-mediated killing activity of SKOV3 and A549 cells .
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 Tcells, CD3+CD4−CD8−(DN) Tcells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (Tcells). Mosunetuzumab redirects Tcells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce Tcell-mediated killing of GPRC5D-expressing MM cells through Tcell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on Tcells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides Tcells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
Pavurutamab (AMG-701) is a bispecific Tcell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on Tcells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes Tcell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
Runimotamab (RG-6194) is a HER2 and CD3Tcell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
BMS-243117 is a potent, and selective benzothiazole based p56 Lck inhibitor with an IC50 of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL (human peripheral blood T-cells) proliferation with an IC50 of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck .
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
Forimtamig (RG-6324) is a GPRC5DxCD3T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
Antitumor agent-37 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-37 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-37 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-37 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
Antitumor agent-36 possesses potent anti-proliferative and anti-metastasis activities. Antitumor agent-36 induces serious DNA damage and further leads to high expression of γ-H2AX and p53. Antitumor agent-36 promotes apoptosis of tumor cells through mitochondrial apoptotic pathway Bcl-2/Bax/caspase3. Antitumor agent-36 significantly improves immune response through restraining the expression of PD-L1 to increase CD3+ and CD8+ T infiltrating cells in tumor tissues .
ITK degrader 1 is a highly selective degrader of interleukin-2-inducible T-cell kinase (ITK; DC50=3.6 nM in vivo in mice), with good plasma exposure levels. ITK degrader 1 induces rapid, and prolonged ITK degradation and suppresses IL-2 secretion (EC50=35.2 nM, Jurkat cells) stimulated by anti-CD3 antibodyin vivo. ITK degrader 1 consists of target protein ligand (red part) ITK ligand 1 (HY-168387), PROTAC linker (black part) Piperidine-C2-piperazine-Boc (HY-168388) and E3 ubiquitinase ligand (blue part) Thalidomide 5-fluoride (HY-W087383). E3 ubiquitinase and PROTAC linker can form Thalidomide-piperidine-C2-piperazine-Boc (HY-168389) .
HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on Tcells, and to serum albumin. HPN536 specifically redirects Tcells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation .
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting Tcells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on Tcells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
MCE Mouse CD3+TCells Negative Selection Kit is designed for the isolation of CD3+Tcells from single cell suspensions of mouse spleen cells and lymph nodes.
MCE Human CD3/CD28 TCell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid Tcell activation.
Vepsitamab (AMG 199) is an anti-MUC17/CD3 BiTE antibody that binds to CD3 on Tcells and MUC17 expressed on tumor cells, mediates redirected tumor cell lysis, and induces Tcell activation and proliferation .
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on Tcells and induces Tcell-mediated cytotoxicity leading to Tcell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate Tcells. Muromonab blocks the function of Tcell receptors to recognize foreign antigens and inhibits Tcell-mediated immune responses, including cell-mediated lymphocyte lysis and Tcell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients .
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic Tcells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces Tcell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research .
Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on Tcells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
Etentamig is a BCMA × CD3 bispecific T-cell engager (BiTE) that can inhibit the activity of B-cell maturation antigen (BCMA) and activate the T-cell surface glycoprotein CD3 complex. Etentamig can be used for research in multiple myeloma, immunoglobulin light chain amyloidosis, and cardiovascular diseases .
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates Tcells by simultaneously binding to CD123 in target cells and CD3 in effector Tcells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .
Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma .
Dafsolimab (SPV-T3a) is an IgG2a murine monoclonal antibody (anti-CD3). Dafsolimab can induce cell death through modulation and activation of the CD3/Tcell receptor complex. Dafsolimab can be used for the research of graft-versus-host disease (GVHD) .
Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3, belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of Tcells, recruiting Tcells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive Tcells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
Cibisatamab, a Tcell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on Tcells. Cibisatamab triggers Tcell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody that specifically binds to B cell maturation antigen (BCMA) and CD3 of Tcells, thereby directing Tcells to multiple myeloma (MM) cells expressing BCMA and activating Tcells to kill tumor cells. Linvoseltamab can be used in research of relapsed/refractory multiple myeloma (RRMM) .
SAR442257 is a humanized IgG4-S228P, kappa monoclonal antibody targeting CD38 and CD28 on multiple myeloma cells and co-stimulates CD3 and CD28 on Tcells .
Voxalatamab (JNJ-63898081) is a bispecific IgG4 antibody targeting PSMA and CD3. Voxalatamab attacks PSMA-expressing tumor cells by activating Tcells. Voxalatamab has anticancer activity and is being studied for the treatment of solid tumors such as prostate cancer .
Vibecotamab (XmAb14045) is a potent bispecific antibody against CD123 and CD3 that stimulates Tcell-mediated targeted killing of CD123-expressing cells. Vibecotamab has antitumor activity and can be used in acute myeloid leukaemia studies .
ERY-974 is a T-cell-engaging bispecific antibody (TCB) targeting GPC3. ERY-974 binds to both GPC3 and the CD3 receptor on Tcells simultaneously, activating Tcells and prompting them to release perforin and granzyme, triggering apoptosis of tumor cells. ERY-974 is promising for research of solid tumors, such as liver cancer .
Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on Tcells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of Tcells against MM tumor cells .
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic Tcells to kill CD20 + expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
AR20.5 is a human monoclonal antibody (mAb) targeting MUC1. AR20.5 increases the number of activated CD8 Tcells, CD3+CD4−CD8−(DN) Tcells, and mature dendritic cells in pancreatic tumor-bearing mice. AR20.5 can be used in anti-pancreatic cancer immunity research .
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (Tcells). Mosunetuzumab redirects Tcells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce Tcell-mediated killing of GPRC5D-expressing MM cells through Tcell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on Tcells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
Anti-DLL3 Antibody (anti-DLL3 arm derived from AMG-757) is the anti-DLL3 arm of the bispecific T-cell engager (BiTE) antibody-Tarlatamab (AMG-757) (HY-P99575). Tarlatamab targets both DLL3 and CD3.
Tebentafusp (IMCgp100) is a bispecific fusion protein to target gp100 peptide-HLA-A*02:01 (a melanoma-associated antigen). Tebentafusp guides Tcells to kill gp100-expressing tumor cells via a high affinity T-cell receptor (TCR) binding domain and an anti-CD3T-cell engaging domain. Tebentafusp leads to inflammatory cytokines and cytolytic proteins production, resulting in the direct lysis of tumour cells .
Pavurutamab (AMG-701) is a bispecific Tcell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on Tcells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes Tcell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .
Runimotamab (RG-6194) is a HER2 and CD3Tcell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
Forimtamig (RG-6324) is a GPRC5DxCD3T-cell-engaging bispecific antibody. Forimtamig has a 2 + 1 format, comprising two high-affinity GPRC5D binding moieties and one CD3 binder. Forimtamig further features a P329G LALA mutated Fc domain that inhibits Fcγ receptor and C1q binding, yet retains binding to the neonatal Fc receptor. The isotype control for Forimtamig can refer to Human IgG1 kappa, Isotype Control (HY-P99001) .
HPN536 is a trispecific, T-cell-activating protein-based construct, which binds to mesothelin-expressing tumor cells, CD3ε on Tcells, and to serum albumin. HPN536 specifically redirects Tcells for potent redirected lysis of mesothelin-expressing cancer cells with concomitant T-cell activation .
Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting Tcells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines .
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on Tcells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
AMG-424 (XmAb968) is a human bispecific antibody (bsAb) targeting CD38 & CD3E. AMG-424 kills CD38-expressing cancer cells, triggers T-cell proliferation and attenuates cytokine release. AMG 424 has antitumor activity in a bone marrow-invasive mouse cancer model and induces peripheral B-cell depletion in cynomolgus monkeys. AMG-424 can be used in multiple myeloma research. Recommended isotype control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .
CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-6*His labeled tag.
CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (HEK293, His) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-6*His labeled tag.
CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.
The CD3 ε protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When APC is activated, TCR signals transmitted by CD3D, CD3E, CD3G, and CD3Z initiate pathways through ITAM. CD3 epsilon Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.
CD3 zeta/CD247 is a component of the TCR-CD3 complex and can transmit APC-induced TCR signals to initiate immune responses. CD3D, CD3E, CD3G, and CD3Z contain ITAMs that are phosphorylated by LCK and FYN upon TCR engagement, providing docking sites for ZAP70. CD3 zeta/CD247 Protein, Human (GST) is the recombinant human-derived CD3 zeta/CD247 protein, expressed by E. coli , with N-GST labeled tag.
CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-His labeled tag.
CD3 δ protein is a component of the TCR-CD3 complex on T lymphocytes and plays a crucial role in adaptive immunity. Activated by APC, TCR signals through the CD3 chain, including CD3D, CD3E, CD3G, and CD3Z. CD3 delta Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 delta protein, expressed by HEK293 , with C-hFc labeled tag.
CD3γ protein on lymphocytes is a component of the TCR-CD3 complex and is critical for adaptive immune responses. When the TCR is activated, CD3D, CD3E, CD3G, and CD3Z transmit TCR-mediated signals and activate downstream pathways. CD3 gamma Protein, Cynomolgus (P.pastoris, His) is the recombinant cynomolgus-derived CD3 gamma protein, expressed by P. pastoris , with N-His labeled tag.
CD3 epsilon Protein, a vital component of the TCR-CD3 complex on T-lymphocytes, is pivotal for adaptive immune responses. CD3E is crucial for proper T-cell development and contributes to TCR-CD3 complex internalization and down-regulation. CD3 epsilon Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.
CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon Protein, Human (104a.a, HEK293, Fc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-hFc labeled tag.
CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3 epsilon 1-27 peptide Protein, Human (HEK293, mFc) is the recombinant human-derived CD3 epsilon protein, expressed by HEK293 , with C-mFc labeled tag.
CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Human (HEK293, His) is the recombinant human-derived CD3D protein, expressed by HEK293 , with C-6*His labeled tag.
CD3 epsilon is an important component of the TCR-CD3 complex on T lymphocytes and promotes TCR-mediated signaling. When APC activates the TCR, CD3 epsilon, together with CD3D, CD3G, and CD3Z, transmits signals across the cell membrane through ITAMs. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc) is a recombinant protein dimer complex containing human-derived CD3E-CD3G Heterodimer protein, expressed by HEK293 , with C-hFc, C-Flag, C-mFc labeled tag. CD3E-CD3G Heterodimer Protein, Human (HEK293, Fc-Flag & mFc), has molecular weight of 42-47 kDa.
The CD3D protein is an important component of the TCR-CD3 complex on T lymphocytes and is critical for adaptive immune responses. After APC activates TCR, CD3D, together with CD3E, CD3G and CD3Z, transmits signals through ITAM and activates downstream pathways. CD3D Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD3D protein, expressed by HEK293 , with C-hFc labeled tag.
The CD3E/CD3 epsilon 1-27 peptide is critical in the TCR-CD3 complex, transmitting signals during T cell activation. When APC activates the TCR, CD3E undergoes LCK/FYN-mediated phosphorylation together with ITAM, initiating downstream signaling. CD3 epsilon Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD3 epsilon protein, expressed by HEK293 , with C-Fc, C-hFc labeled tag.
CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D Protein, Canine (HEK293, Fc) is the recombinant canine-derived CD3D protein, expressed by HEK293 , with C-hFc labeled tag.
CD3D protein is a component of the TCR-CD3 complex on T lymphocytes and plays a key role in adaptive immunity. It transmits signals through the CD3D, CD3E, CD3G, and CD3Z chains upon TCR engagement. CD3D-CD3E Heterodimer Protein, Human (HEK293) is a recombinant protein dimer complex containing human-derived CD3D-CD3E Heterodimer protein, expressed by HEK293 , with tag free. CD3D-CD3E Heterodimer Protein, Human (HEK293), has molecular weight of 44-54 kDa.
CD3 epsilon Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 23 kDa, targeting to CD3 epsilon. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human.
CD3D; T3D; T-cell surface glycoprotein CD3 delta chain; T-cell receptor T3 delta chain; CD antigen CD3d
WB, IHC-F, IHC-P, ICC/IF, IP
Human
CD3D Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 19 kDa, targeting to CD3D. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human.
CD247; CD3Z; T3Z; TCRZ; T-cell surface glycoprotein CD3 zeta chain; T-cell receptor T3 zeta chain; CD antigen CD247
WB, IP
Human
Phospho-CD3 zeta (Tyr142) Antibody (YA2425) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2425), targeting Phospho-CD3 zeta (Tyr142), with a predicted molecular weight of 19 kDa (observed band size: 19 kDa). Phospho-CD3 zeta (Tyr142) Antibody (YA2425) can be used for WB, IP experiment in human background.
Product Comparison
Compare
Clear All
Compare Products
Products
In-stock
-
+
Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample
YesNo
Size
* This product has been "discontinued".
Optimized version of product available:
/
In-stock
-
+
Add to Cart
Get quote
Inquiry Online
Your information is safe with us. * Required Fields.
